This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

In February 2018, FDA issued a draft product-specific guidance for industry on generic loteprednol etabonate. We are now issuing revised draft guidance for industry that replaces the previously issued guidance.

**Active Ingredient:** Loteprednol etabonate  
**Dosage Form; Route:** Suspension/drops; ophthalmic  
**Strength:** 0.5%  
**Recommended Studies:** Two options: in vitro or in vivo study

---

**I. In vitro option:**

To qualify for the in vitro option for this drug product all of the following criteria should be met:
i. The test and Reference Listed Drug (RLD) formulations are qualitatively (Q1)\(^1\) and quantitatively (Q2)\(^2\) the same (Q1/Q2)\(^3\).

ii. Acceptable comparative physicochemical characterization of the test and Reference Standard (RS) products. The comparative study should be performed on at least three batches of both the test and RS products and should include:\(^4\)
   - Appearance, pH, specific gravity, osmolality, surface tension, and viscosity
   - Soluble fraction of loteprednol etabonate in the final drug product
   - Dose concentration (one or two drops per dose) of loteprednol etabonate from a minimum of ten units from three batches each of the test and RS products at beginning, middle, and end of the unit. The dose concentration should be compared using the population bioequivalence (PBE) statistical procedure (95% upper confidence bound). Refer to the product-specific guidance on Budesonide inhalation suspension for additional information regarding PBE.
   - Drug particle size distribution. The particle size distribution should be compared using PBE (95% upper confidence bound) based on D\(_{50}\) and SPAN [i.e. (D\(_{90}\)-D\(_{10}\))/D\(_{50}\)]. The applicant should provide no fewer than ten data sets each batch from three different batches of both the test and reference products for PBE analysis. Full profiles of the particle size distributions should also be submitted for all samples tested.

iii. Acceptable comparative in vitro drug release of loteprednol etabonate from the test and RS formulations. Detailed information on development and validation of a proposed in vitro drug release testing method should be provided.

---

II. In vivo option:

Type of study: Bioequivalence study with pharmacokinetic (PK) endpoints

Design: Single-dose, crossover or parallel design, in vivo in aqueous humor

Strength: 0.5%

Subjects: Patients undergoing indicated cataract surgery and scheduled to receive ophthalmic corticosteroids just prior to their eye surgery.

Additional comments: Specific recommendations are provided below.

Analyte to measure: Loteprednol etabonate in aqueous humor

---

\(^1\) Q1 (Qualitative sameness) means that the test product uses the same inactive ingredient(s) as the reference product.

\(^2\) Q2 (Quantitative sameness) means that concentrations of the inactive ingredient(s) used in the test product are within \(\pm 5\%\) of those used in the reference product.

\(^3\) For ophthalmic drug products, FDA has determined that, as a scientific matter, any qualitative or quantitative deviations from the RLD, even in inactive ingredients listed in 21 CFR 314.94(a)(9)(iv), should be accompanied by an appropriate in vivo BE study or studies. ANDA Submissions –Refuse-to-Receive Standards: Guidance for Industry.

\(^4\) The manufacturing process for the exhibit batches should be reflective of the manufacturing process to be utilized for commercial batches.
**Bioequivalence based on (90% CI):** Loteprednol etabonate

**Additional Comments Regarding the In Vivo Pharmacokinetic Study in Aqueous Humor:**

1. The study is conducted in patients undergoing indicated cataract surgery and scheduled to receive ophthalmic corticosteroids just prior to their eye surgery. A single dose of the test or reference product is instilled into the inferior cul de sac of the eye prior to cataract extraction. Only one single sample of aqueous humor is collected from one eye from each patient, at one assigned sampling time point.

   Applicant may consider a parallel design for the bioequivalence study. If using a parallel study design, please note that each patient should receive only one treatment, test or reference, but not both. Alternatively, a crossover study design may be used in patients undergoing indicated cataract surgery for both eyes. When crossover study design is used, each patient should receive both test and reference treatments. The wash-out period for the crossover study should not exceed 35 days.

2. In order to demonstrate bioequivalence, an adequate estimation of the rate (Cmax) and extent (AUC) of loteprednol etabonate absorption is needed.

   The following statistical model is recommended:

   The mean AUC\(_t\) for each product and time point \(t\) of measurement is calculated by using the mean concentrations (\(\bar{C}_t\)) at each time point \(t\) to derive the mean profile for each product. On the basis of the trapezoid rule, mean AUC\(_t\) is computed as the weighted linear combination of these mean concentrations at each time point through time \(t\). The AUC\(_t\) is the area under the concentration-time curve from zero to the time \(t\). Generally, we have \(j\) concentration measurements at times \(t_1 < t_2 < t_3 < \ldots < t_j\) (\(t_1 > 0\)).

\[
AUC_{t,j} = t_1 \times \bar{C}_{t_1} / 2 + \sum_{i=1}^{j-1} \left( \bar{C}_{t_i} + \bar{C}_{t_{i+1}} \right) \times (t_{i+1} - t_i) / 2
\]

The ratio (Rt) of AUC\(_t\) from the test product to AUC\(_t\) from the reference product is used to assess bioequivalence for AUC\(_0\)-\(t\). Estimation of the standard deviation(s) and confidence interval of Rt may be done by bootstrap techniques or a parametric method.

Bioequivalence is supported if the 90% confidence interval for Rt (\(R_t \pm 1.645 \, s_t\)) lies within (0.8, 1.25). The bootstrapping technique or a parametric method can be used to determine Cmax and Tmax and assess bioequivalence for Cmax.
Revision History:  Recommended March 2011; Revised March 2012, June 2012, April 2013, June 2016, February 2018, August 2021

Unique Agency Identifier:  PSG_020583